Cargando…

Immunogenicity of inactivated COVID-19 vaccines at different vaccination intervals

To evaluate the immunogenicity of inactivated COVID-19 vaccines administered at different intervals. Subjects who had received two doses of inactivated COVID-19 vaccines at an interval of 21 days or 1–7 months were selected to collect 5 ml of venous blood after the second dose for the detection of s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Juan, Chen, Weixin, Chen, Meng, Bai, Shuang, Yuan, Qianli, Wu, Jiang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2021
Materias:	Short Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8425430/ https://www.ncbi.nlm.nih.gov/pubmed/34348570 http://dx.doi.org/10.1080/21645515.2021.1945902

Ejemplares similares

The safety and immunogenicity to inactivated COVID-19 vaccine in patients with hyperlipemia
por: Yang, Lei, et al.
Publicado: (2023)

Comparison of the reactogenicity and immunogenicity of a reduced and standard booster dose of the mRNA COVID-19 vaccine in healthy adults after two doses of inactivated vaccine
por: Kanokudom, Sitthichai, et al.
Publicado: (2022)

Safety and immunogenicity of the first Kazakh inactivated vaccine for COVID-19
por: Nurpeisova, Ainur, et al.
Publicado: (2022)

CpG 684: an effective adjuvant for the inactivated COVID-19 vaccine in mice
por: Liu, Jiandong, et al.
Publicado: (2023)

Immunogenicity and safety of the 2015 Southern Hemisphere formulation of a split-virion inactivated quadrivalent vaccine
por: Montalban, Cecilia, et al.
Publicado: (2017)

Adverse events of inactivated COVID-19 vaccine in HIV-infected adults
por: Wu, Songjie, et al.
Publicado: (2021)

Immunogenicity of inactivated COVID-19 vaccine in patients with autoimmune inflammatory rheumatic diseases
por: Zheng, Yi-Qing, et al.
Publicado: (2022)

Effect of seasonal coronavirus immune imprinting on the immunogenicity of inactivated COVID-19 vaccination
por: Yin, Di, et al.
Publicado: (2023)

Low toxicity and high immunogenicity of an inactivated vaccine candidate against COVID-19 in different animal models
por: Wang, Ze-Jun, et al.
Publicado: (2020)

The safety and immunogenicity of inactivated COVID-19 vaccine in old pulmonary tuberculosis patients
por: Yang, Lei, et al.
Publicado: (2023)

Safety and immunogenicity of heterologous recombinant protein subunit vaccine (ZF2001) booster against COVID-19 at 3–9-month intervals following two-dose inactivated vaccine (CoronaVac)
por: Liao, Yuting, et al.
Publicado: (2022)

Comparative immunogenicity of mRNA and inactivated vaccines against COVID-19
por: Lim, Wey Wen, et al.
Publicado: (2021)

Immunogenicity of SARS inactivated vaccine in BALB/c mice
por: Xiong, Sheng, et al.
Publicado: (2004)

Immunogenicity and safety of an intramuscular split-virion quadrivalent inactivated influenza vaccine in individuals aged ≥ 6 months in India
por: Agarkhedkar, Sharad, et al.
Publicado: (2019)

Vaccine subtype and dose interval determine immunogenicity of primary series COVID-19 vaccines in older people
por: Parry, Helen, et al.
Publicado: (2022)

Development and immunogenicity evaluation of porcine deltacoronavirus inactivated vaccine with different adjuvants in mice
por: Zhao, Fu-jie, et al.
Publicado: (2022)

Impact of various vaccine boosters on neutralization against omicron following prime vaccinations with inactivated or adenovirus-vectored vaccine
por: Huang, Qingrui, et al.
Publicado: (2022)

Assessment of Post-Vaccination Immunologic Responses in Inactivated Virus COVID-19 Respondents
por: Setianingrum, Elisabeth L. S., et al.
Publicado: (2023)

Immunogenicity and safety of a trivalent inactivated influenza vaccine produced in Shenzhen, China versus a comparator influenza vaccine: a phase IV randomized study
por: Hu, Yuemei, et al.
Publicado: (2019)

Immunogenicity and safety among laboratory workers vaccinated with Bexsero® vaccine
por: Hong, Eva, et al.
Publicado: (2016)

The kinetics of IgG subclasses and contributions to neutralizing activity against SARS‐CoV‐2 wild‐type strain and variants in healthy adults immunized with inactivated vaccine
por: Chen, Weixin, et al.
Publicado: (2022)

Safety and Immunogenicity of Inactivated COVID-19 Vaccines Among People Living with HIV in China
por: Han, Xiaoxu, et al.
Publicado: (2022)

Immunogenicity of heterologous inactivated and adenoviral-vectored COVID-19 vaccine: Real-world data
por: Wanlapakorn, Nasamon, et al.
Publicado: (2022)

Safety and Immunogenicity of the Inactivated COVID-19 Vaccine Booster in People Living with HIV in China
por: Yi, Yunyun, et al.
Publicado: (2023)

Immunogenicity Evaluating of the Multivalent COVID-19 Inactivated Vaccine against the SARS-CoV-2 Variants
por: Zhang, Yuntao, et al.
Publicado: (2022)

Immunogenicity of Fractional Dose Inactivated Poliovirus Vaccine in India
por: Ahmad, Mohammad, et al.
Publicado: (2021)

Safety and Immunogenicity of the Third Booster Dose with Inactivated, Viral Vector, and mRNA COVID-19 Vaccines in Fully Immunized Healthy Adults with Inactivated Vaccine
por: Kanokudom, Sitthichai, et al.
Publicado: (2022)

Safety, immunogenicity, and immune persistence of two inactivated COVID-19 vaccines replacement vaccination in China: An observational cohort study
por: Wang, Xiaoqi, et al.
Publicado: (2022)

Safety of inactivated COVID-19 vaccine in tuberous sclerosis complex patients with epilepsy treated with rapamycin
por: Lu, Qian, et al.
Publicado: (2022)

Immunogenicity and protective efficacy in monkeys of purified inactivated Vero-cell SARS vaccine
por: Qin, Ede, et al.
Publicado: (2006)

Immunogenicity and safety of inactivated and mRNA COVID-19 vaccines in patients with systemic lupus erythematosus
por: So, Ho, et al.
Publicado: (2022)

Immunogenicity of the COVID-19 BNT162b2 vaccine in adolescents and young adults with cystic fibrosis
por: Michos, Athanasios, et al.
Publicado: (2022)

Safety and immunogenicity of COVID-19 vaccination in patients with non-alcoholic fatty liver disease (CHESS2101): A multicenter study
por: Wang, Jitao, et al.
Publicado: (2021)

Safety and Immunogenicity of Inactivated Bacillus subtilis Spores as a Heterologous Antibody Booster for COVID-19 Vaccines
por: Sung, Johnny Chun-Chau, et al.
Publicado: (2022)

Safety and immunogenicity of inactivated COVID-19 vaccine in patients with metabolic syndrome: A cross-sectional observational study
por: Guo, Qiao, et al.
Publicado: (2022)

Safety and immunogenicity of inactivated COVID-19 vaccine CoronaVac and the RBD-dimer–based COVID-19 vaccine ZF2001 in chronic hepatitis B patients
por: Wu, Shiheng, et al.
Publicado: (2023)

Immunogenicity of an Inactivated Canine Adenovirus Type 1 Vaccine for Foxes
por: Fu, Yang, et al.
Publicado: (2022)

Safety and immunogenicity of inactivated COVID-19 vaccination in adult rheumatic patients in South China: a prospective study
por: Zeng, Huiqiong, et al.
Publicado: (2022)

Safety and immunogenicity of a heterologous booster with an RBD virus-like particle vaccine following two- or three-dose inactivated COVID-19 vaccine
por: Yong, Xiaolan, et al.
Publicado: (2023)

Ameliorated immunity elicited by intradermal inoculation in individuals vaccinated with inactivated SARS-CoV-2 vaccine
por: Fan, Shengtao, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_tfnf2tcef0j9reh59gkfpiaavo